Atea Pharmaceuticals Announces Closing of Initial Public Offering
November 03 2020 - 4:01PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing antiviral therapeutics to improve
the lives of patients suffering from life-threatening viral
infections, today announced the closing of its initial public
offering of 14,375,000 shares of common stock, including the
exercise in full by the underwriters of their option to purchase up
to 1,875,000 additional shares of common stock, at a public
offering price of $24.00 per share. The aggregate gross proceeds to
Atea from the offering were $345 million, before deducting
underwriting discounts and commissions and other offering expenses.
All of the shares in the offering were offered by Atea
Pharmaceuticals. Atea’s common stock began trading on the Nasdaq
Global Select Market under the ticker symbol “AVIR” on October 30,
2020.
J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC,
Evercore Group L.L.C. and William Blair & Company, L.L.C. acted
as joint book-running managers of the offering.
A registration statement on Form S-1 (File No. 333-249404)
relating to the offering has been filed with the Securities and
Exchange Commission and became effective on October 29, 2020. The
offering was made only by means of a prospectus. Copies of the
final prospectus relating to the offering may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, telephone:
866-803-9204; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd
Floor, New York, NY 10014, Attention: Prospectus Department, or by
email at prospectus@morganstanley.com; Evercore Group, L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com; or William Blair & Company,
L.L.C., Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by
email at prospectus@williamblair.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contacts
Investors:Will O’ConnorStern Investor
Relations212-362-1200will.oconnor@sternir.com
Media:Carol Guaccero301-606-4722contactus@ateapharma.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Sep 2023 to Sep 2024